CSFZX
Price
$59.99
Change
+$0.58 (+0.98%)
Updated
Jun 12 closing price
Net Assets
2.28B
JERAX
Price
$13.16
Change
+$0.07 (+0.53%)
Updated
Jun 11 closing price
Net Assets
339.13M
Interact to see
Advertisement

CSFZX vs JERAX

Header iconCSFZX vs JERAX Comparison
Open Charts CSFZX vs JERAXBanner chart's image
CSFZX vs JERAX Comparison Chart in %
View a ticker or compare two or three
VS
CSFZX vs. JERAX commentary
Jun 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSFZX is a Buy and JERAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CSFZX has more cash in the bank: 2.28B vs. JERAX (339M). CSFZX pays higher dividends than JERAX: CSFZX (3.24) vs JERAX (2.78). CSFZX was incepted earlier than JERAX: CSFZX (12 years) vs JERAX (19 years). JERAX (0.99) is less costly to investors than CSFZX (0.84). JERAX is a more actively managed with annual turnover of: 61.00 vs. CSFZX (57.00). CSFZX has a lower initial minimum investment than JERAX: CSFZX (0) vs JERAX (2500). CSFZX (13.15) and JERAX (12.84) have marching annual gain over last year. CSFZX return over 5 years is better than : 8.00 vs. JERAX (-3.10).
CSFZXJERAXCSFZX / JERAX
Total Expense Ratio0.840.9985%
Annual Report Gross Expense Ratio0.840.9985%
Fund Existence12 years19 years-
Gain YTD9.9739.594104%
Front LoadN/A6%-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets2.28B339M673%
Annual Yield % from dividends3.242.78117%
Returns for 1 year13.1512.84102%
Returns for 3 years31.9526.48121%
Returns for 5 years8.00-3.10-258%
Returns for 10 years60.6664.9393%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STKE1.270.06
+5.37%
Sol Strategies Inc
CAMT193.279.12
+4.95%
Camtek Ltd
DCOM40.080.27
+0.68%
Dime Commercial Bancshares, Inc.
OXLCN24.930.01
+0.04%
Oxford Lane Capital Corp
LRMR3.47-0.13
-3.61%
Larimar Therapeutics